close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.920 +0.110 (+1.89%)
Streaming Delayed Price Updated: 9:52 AM EDT, Sep 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Alvotech's Earnings Outlook ↗
 
Via Benzinga
News headline image
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
News headline image
ALVO Stock Earnings: Alvotech Misses Revenue for Q2 2024 ↗
ALVO stock results show that Alvotech missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
News headline image
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars ↗
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
News headline image
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Alvotech
Via GlobeNewswire
News headline image
Vipshop, Hesai Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
News headline image
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Closing of Private Debt Financing
From Alvotech
Via GlobeNewswire
News headline image
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
News headline image
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Issues New Shares to Holders of Convertible Bonds
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and STADA add to strategic alliance through denosumab partnership
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Strategic Refinancing Agreement
From Alvotech
Via GlobeNewswire
News headline image
2 Generic Drug Makers With Growing Runways
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. 
Via MarketBeat
Topics Intellectual Property
News headline image
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
From Alvotech
Via GlobeNewswire
News headline image
ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024 ↗
ALVO stock results show that Alvotech missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Stocks Hold Steady On Mixed Fed Remarks, First Solar Rallies, Bitcoin Falls Below $70,000: What's Driving Markets Tuesday? ↗
It’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York. 
Via Benzinga
Topics Economy
News headline image
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.